Series A Preferred Stock Financing for Oncology Focused Biotechnology Company

Represented Canaan Partners in connection with the Series A preferred stock financing of IDEAYA Biosciences, Inc.  IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment.  IDEAYA Biosciences, Inc. has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. 

For more information, please click here.